Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

NCT06005324 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

HPV-Negative Squamous Cell Carcinoma

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Cetuximab
RADIATION: Standard Dose Radiation
RADIATION: Low Dose Radiation
DRUG: Cisplatin
DRUG: TFHX Regimen

Sponsor

University of Chicago